Match the Assessment to the Question
A single-dose or multiple-dose assessment is not simply a choice between a shorter and a longer study. The choice determines which dosing condition the comparison represents. A single-dose assessment compares the products after one administration. A multiple-dose assessment compares them under a specified repeated-dose regimen; when the question concerns steady-state exposure, sampling must occur after steady state has been reached.
The starting point is therefore the intended inference. Is the question whether the products give comparable exposure after one dose under controlled conditions? Or is the question about exposure during the prescribed repeated regimen, where steady-state information is needed? Choosing an assessment before stating that question risks collecting data that are precise but do not address the intended comparison.
These are assessment conditions, not different definitions of bioequivalence. The comparison still needs an appropriate study design, controlled administration, suitable pharmacokinetic measurements, and a prespecified analysis. The choice between one dose and repeated dosing does not, by itself, determine whether the study is valid or what conclusions its results support.
A Decision Framework
First specify the clinical and product question. State the product(s), dose, dosing conditions, and the exposure of interest. If food conditions matter, use the intended fed or fasted condition consistently with the question. A comparison conducted after a dose in the fasted state does not, by itself, answer a question about administration with food.
Next ask whether one dose can answer that question. Single-dose assessment is generally attractive when exposure following one dose is measurable and informative, and the goal is to compare the formulations under that defined condition. It usually avoids the additional time, doses, and adherence demands of a repeated-dose regimen. It can also limit exposure to a potentially poorly tolerated product.
Multiple-dose assessment is appropriate when the target question specifically concerns exposure during repeated use, particularly when steady-state information is needed to characterize the comparison. It can also be considered when concentrations after a single dose would not be measured adequately but concentrations under the intended repeated regimen are measurable. That practical advantage does not make the result a substitute for a single-dose comparison: the inference is tied to the repeated-dose conditions studied.
The decision can be summarized as an alignment problem: the assessment condition must match the condition about which a conclusion is sought. If the intended conclusion concerns the products after one dose, a steady-state comparison answers a different question. If the intended conclusion concerns steady-state use, a single-dose comparison alone may leave that question unresolved.
Specify the products, dose, fed or fasted condition, and whether the question concerns a single administration or the repeated clinical regimen.
Consider whether exposure after one dose can be measured with adequate precision and whether it represents the question of interest.
If the target is exposure under a chronic regimen or specifically at steady state, plan repeated dosing and sampling that support that target.
Account for study duration, assay capability, adherence, tolerability, and whether the additional information justifies the added burden.
Worked Decisions
Worked Example: A Measurable Single-Dose Comparison
Suppose a hypothetical immediate-release medicine is administered once daily. The study question is whether two formulations give comparable exposure after one 100 mg dose in the fasted state. A preliminary assay review indicates that concentrations after this dose are expected to remain quantifiable across the planned sampling period. The available pharmacokinetic information does not indicate that the one-dose comparison fails to represent the specified question.
For planning, assume a two-period crossover with 24 participants and 12 blood samples per period. The planned total number of samples is \(24 \times 2 \times 12 = 576\). If each period instead required seven days of dosing with the same 12 samples on each day, the count would be \(24 \times 2 \times 7 \times 12 = 4{,}032\) samples.
The arithmetic does not prove that the smaller study is adequate: sample size, design, and assay performance still require appropriate justification. It does show the practical cost of repeated daily sampling in this plan. Because the question is explicitly about one dose and the expected concentrations are measurable, a single-dose assessment is aligned with the question and avoids repeated dosing that would not add the requested information.
Worked Example: Steady-State Information Is the Target
Consider a hypothetical medicine prescribed every 24 hours, where the comparison question is whether two formulations give comparable exposure during continued treatment, including the concentration immediately before the next dose. The target is not limited to the response after the first administration.
Suppose a single-dose pilot found concentrations near the end of the 24-hour interval of 0.08 mg/L and 0.10 mg/L for the two formulations, while the assay’s lower limit of quantification is 0.12 mg/L. Since both expected values are below that limit, those measurements cannot reliably characterize exposure at the time of interest after one dose. A repeated-dose assessment is a reasonable candidate because the intended question concerns continued dosing and the single-dose measurements are inadequate for that part of the question.
The decision is conditional, not automatic. The study must use the specified 24-hour regimen, establish that steady state has been reached before the relevant sampling, and demonstrate that the assay can quantify the concentrations needed for the comparison. If those conditions cannot be met, simply giving more doses does not solve the measurement problem. This assessment would support an inference about the studied repeated-dose condition, not an unrestricted claim about every dose or dosing condition.
Worked Example: Added Doses Do Not Fix a Mismatched Question
A hypothetical product is intended to be administered once with a meal. The stated question is whether the two formulations give comparable exposure following that single fed administration. A proposed study instead administers each product once daily for six days and compares exposure on the final day. Assume the plan uses 20 participants, two periods, and 10 samples on the final sampling day in each period. The final-day sampling count is \(20 \times 2 \times 10 = 400\) samples, excluding samples collected on the preceding dosing days.
The number of samples is calculable, but it does not establish that this is the right assessment. The study compares the products under repeated fed dosing, not after the single fed administration in the question. Unless the target is revised to concern repeated use, the extra doses add burden without aligning the assessment to the stated inference. The appropriate choice for the stated question is a single-dose fed comparison, with meal conditions standardized. If the clinical question changes to repeated fed use, the study objective and assessment conditions must be reconsidered together.
Justifying the Choice and Checking Assumptions
The justification follows from the target of inference. Let \(Q\) denote the condition about which the product comparison is intended to make a statement. Let \(D\) denote the condition actually used in the assessment, including the number of doses and the fed or fasted state. An assessment is directly aligned when \(D\) represents \(Q\); when it does not, the study requires an additional argument that results under \(D\) apply to \(Q\).
This is a design justification, not a statistical test. It explains why a well-measured result under the wrong dosing condition may not answer the clinical question. For example, evidence after one dose supports a one-dose comparison under the studied conditions. It does not automatically establish the same comparison during repeated dosing.
The selection also relies on practical assumptions that should be checked. The prescribed dose and administration conditions must be implemented consistently; the assay must measure the concentrations relevant to the target; and the chosen schedule must permit the intended interpretation. For a steady-state question, the study must establish that the sampling period follows steady state rather than assume it from the number of doses. The precise assessment of steady state is a separate design task.
If available evidence suggests that pharmacokinetics change with dose or repeated administration, results from one dosing condition may not represent another. In that situation, do not assume that a single-dose comparison predicts a repeated-dose comparison, or that a repeated-dose result generalizes to single administration. The design should be justified for the condition of interest, and uncertainty about the relationship between conditions should be made explicit.
Comparing the Approaches
| Consideration | Single-dose assessment | Multiple-dose assessment |
|---|---|---|
| Question directly addressed | Exposure following one administration under specified conditions | Exposure under repeated administration; steady-state questions require steady-state sampling |
| Study burden | Usually fewer doses and a shorter dosing schedule | More doses, longer participation, and greater adherence demands |
| Measurement concern | May be unsuitable if relevant concentrations after one dose are below assay capability | May improve measurability under repeated use, but the assay still must be fit for purpose |
| Interpretive limitation | Does not automatically characterize repeated-dose exposure | Does not automatically answer a single-dose question or generalize beyond the regimen studied |
Neither column is universally preferable. The choice depends on the study question, the ability to measure the relevant exposure, and the costs and risks of the dosing schedule. A repeated-dose assessment is not inherently more clinically relevant; it is more relevant only when repeated use is the target.
Diagnostics, Limitations, and Common Pitfalls
Before committing to a design, examine whether the proposal could fail to answer its own question. Review assay limits against the expected concentration-time profile, confirm that the sampling schedule covers the intended exposure period, and verify that dose administration and meal conditions are specified. For a multiple-dose assessment, include a defensible plan for confirming that steady state precedes the comparison sampling. For either assessment, review expected tolerability and the feasibility of completing the required procedures.
A mismatch between the question and the dosing condition is a conceptual failure, even if the measurements are precise. Other warning signs include relying on concentrations below the assay’s quantification limit, treating a planned number of repeated doses as proof of steady state, and extending conclusions to an unstudied regimen without justification. If evidence indicates dose-dependent or time-dependent pharmacokinetics, the relationship between single- and repeated-dose results needs particular care.
- Wrong reasoning: “Multiple-dose assessment is always better because patients take the medicine repeatedly.” Correction: Repeated dosing is justified when repeated-use exposure is the target; it may be unnecessary or misaligned for a single-dose question.
- Wrong reasoning: “A single-dose study found comparable exposure, so steady-state exposure must also be comparable.” Correction: That conclusion does not follow without a justified link between the two conditions.
- Wrong reasoning: “The study gave several doses, so sampling must represent steady state.” Correction: The study must establish steady state before sampling intended to characterize it.
The main limitation is that the assessment condition restricts the scope of the conclusion. A single-dose study can be efficient and informative without answering every question about chronic use. A multiple-dose study can address repeated-use exposure without establishing every aspect of a one-dose comparison. State the condition studied and avoid extrapolating beyond it.
Check Your Understanding
For each question, identify the appropriate reasoning. Solutions follow each item.
- A study asks whether two formulations give comparable exposure after one fasted dose, and the expected concentrations are measurable. Should the design use single or multiple dosing?
Solution: Single dosing is aligned with the stated one-dose question. Repeated dosing would add burden without being required by the target.
- A chronic-use comparison requires exposure information during steady-state treatment, but a single-dose pilot predicts concentrations below the assay limit at the relevant sampling time. What should the design team consider?
Solution: Consider a multiple-dose assessment because repeated-use exposure is the target and single-dose measurements are inadequate. Confirm that the assay can measure the repeated-dose concentrations and that steady state is established before sampling.
- Why does a precise comparison after repeated fed dosing not automatically answer a question about one fed administration?
Solution: The dosing conditions differ. The result directly describes repeated fed dosing; applying it to one administration requires a separate, justified link.
- A protocol specifies eight daily doses and labels the final samples “steady state” without supporting evidence. Is that designation sufficient?
Solution: No. The number of doses alone does not establish steady state. The protocol needs a defensible method for confirming that the relevant sampling follows steady state.